Ignite Creation Date:
2024-05-05 @ 4:47 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00318136
Status:
COMPLETED
Last Update Posted:
2010-05-11
First Post:
2006-04-24
Brief Title:
A Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced Previously Untreated Squamous Non-Small Cell Lung Cancer BRIDGE
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
A Pilot Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced Previously Untreated Squamous Non-Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2010-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open-label single-arm multicenter pilot study to evaluate the safety and efficacy of carboplatinpaclitaxelbevacizumab in subjects with locally advanced Stage IIIb with pleural effusionpericardial effusion Stage IV or recurrent squamous Non-Small Cell Lung Cancer NSCLC who have not received prior systemic therapy for metastatic disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None